Colorectal Cancer Clinical Trials & Research at St. Joseph Health Medical Group

Colorectal cancer is the third most common type of cancer in men and women in the U.S. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer.

St. Joseph Health Medical Group is currently enrolling patients for the following colorectal cancer clinical trials:

Gastric Cancer
Colorectal Cancer
​Pancreatic Cancer


Gastric

A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy (BeiGene)

Phase III

The purpose of this study is to compare the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced or inoperable gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Patients must have achieved a partial response that is maintained for ≥ 4 weeks or a complete response with platinum-based first-line chemotherapy.

Treatment agent: BGB-290 (PARPi)
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03427814


Colorectal

A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem)

Phase III

This is an international multi-center, prospective, open-label trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in adult patients with metastatic colorectal cancer following progression on first-line FOLFOX or XELOX with or without bevacizumab.

Treatment agent: Napabucasin
PI: Ian Anderson, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT02753127


Pancreatic Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel andGemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (HALO-109)

Phase III

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). Participants will be randomized in a 2:1 ratio to PAG or AG treatment.

Treatment agent: PEGPH20
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT01839487

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (JIT Sequoia)

Phase III

The purpose of this study is to analyze the clinical use of AM0010 in combination with FOLFOX compared with FOLFOX alone as second-line therapy in patients with advanced metastatic pancreatic cancer that has progressed during or following a first-line gemcitabine containing regimen.

Treatment agent: AM0010 (PEG-rHU IL-10)
PI: Thomas Stanton, MD
Study Coordinator: Kim Young // Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links: clinicaltrials.gov NCT No: NCT02923921

Our Locations